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Abstract
Background: Many people who have common mental disorders, such as depression and anxiety, also have some
psychotic experiences. These experiences are associated with higher clinical complexity, poor treatment response, and
negative clinical outcomes. Psychological interventions have the potential to improve outcomes for people with
psychotic experiences. The aims of this systematic review are to (1) synthesise the evidence on the effectiveness and
cost-effectiveness of psychological interventions to reduce psychotic experiences and their associated distress and (2)
identify key components of effective interventions.
Methods: Our search strategy will combine terms for (1) psychological interventions, (2) psychotic experiences, and (3)
symptoms associated with psychotic experiences. We will search the following online databases: MEDLINE, Embase,
PsycINFO, all Cochrane databases, British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Health Management Information Consortium (HMIC), Education Resources Information Center (ERIC), and
EconLit. Our primary outcome is the proportion of people who recovered or remitted from psychotic experiences after
the intervention. Our secondary outcomes are changes in positive psychotic symptoms, negative psychotic symptoms,
depression, anxiety, functioning (including social, occupational, and academic), quality of life, and cost-effectiveness.
Two independent reviewers will judge each study against pre-specified inclusion and exclusion criteria and will extract
study characteristics, outcome data, and intervention components. Risk of bias and methodological quality will be
assessed using the Effective Public Health Practice Project Quality Assessment Tool for Quantitative Studies and the
Drummond Checklist. Results will be synthesised using random-effects meta-analysis and narrative synthesis.
Discussion: The identification of effective psychological interventions and of specific components associated
with intervention effectiveness will augment existing evidence that can inform the development of a new,
tailored intervention to improve outcomes related to psychotic symptoms, anxiety and depression, distress,
functioning, and quality of life.
Systematic review registration: PROSPERO CRD42016033869
Keywords: Psychosis, Ultra-high risk, At-risk mental state, Psychotic experiences, Psychological intervention,
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Background
Many people who have common mental disorders (i.e.
depressive and anxiety disorders) also have some psy-
chotic experiences such as attenuated paranoia or voice
hallucinations. Findings from large population studies
have shown that these psychotic phenomena co-occur
with depression and anxiety [1]. In fact, psychosis,
depression, and anxiety share mechanisms [2–7] and
causes, including childhood and later trauma [8–10]. Lon-
gitudinal clinical data indicate that psychotic experiences
during adolescence or young adulthood may be associated
with a range of non-psychotic mental disorders later in life
[11]. More generally, psychotic experiences are associated
with higher clinical complexity, poor response to treat-
ment [12–14], bad clinical and functional outcomes, and
increased risk of self-harm [15–19].
This evidence suggests that psychotic experiences
may be useful markers of severity in common mental
disorders [4] in addition to serving as indicators of pos-
sible transition to psychotic illness. Recent research has
found that most people with common mental disorder
with psychotic experiences, regardless of whether they
receive specialised psychological treatment, rarely de-
velop frank psychotic disorders [15, 20]. This suggests
that common mental disorder with psychotic expe-
riences may represent a distinct form of illness that
might benefit from targeted therapeutic approaches. A
reasonable hypothesis is that recovery rates in this
population might be improved by focusing on psychotic
experiences and their associated distress and not exclu-
sively on reducing transitions.
The first challenge is the accurate identification and
treatment of common mental disorder with psychotic ex-
periences. Current psychiatric diagnostic classifications
[21, 22] do not acknowledge the presence of psychotic ex-
periences in more common depressive or anxiety disor-
ders. Indeed, very few clinical measurement scales for
common psychiatric morbidity include psychotic experi-
ences [1]. These experiences do not necessarily reach the
threshold for treatment in specialised secondary care ser-
vices in the first instance and often remain undetected in
more general health care settings. For example, people
with common mental disorders in England are usually
treated in primary care; most are referred to Improving
Access to Psychological Therapies (IAPT) services, also
called Psychological Wellbeing Services, which were
developed to enable more people with common mental
disorders to access talking therapies. These services treat
more than 1,000,000 people a year, providing steps 2 and
3 in the four-step model of care following the National
Institute for Health and Care Excellence (NICE) guidelines
for depression [23] and anxiety and related disorders [24].
They mostly offer standard cognitive behavioural therapy
(CBT) for people aged 16 to 65. As in other primary care
settings, psychotic experiences are not routinely measured
in the IAPT population nor taken into account in therapy
[25]. Yet, within IAPT, psychotic experiences are relatively
common; results from a recent study showed that ap-
proximately 30% of individuals in step 3 reported having
these experiences [25]. Also, psychotic experiences were
associated with higher depression and anxiety scores be-
fore and after the initial period of therapy, indicating poor
recovery [25]. This suggests strongly that people with
psychotic experiences may fall into a service gap because
their symptoms neither reach the increasingly high thresh-
old for secondary care, nor are they explicitly and ad-
equately addressed by standard psychological therapies.
To date, the psychological intervention for addressing
psychotic experiences that has been most investigated is
CBT [26]. Other types of psychological therapies and
interventions (e.g. mindfulness interventions, behaviour
therapy) for psychotic experiences are less frequently
studied [27]. Additionally, while psychological therapy
has been shown to reduce psychotic experiences [28–
30], less is known about its effects on other symptoms
such as distress, sleep, social interaction, or functioning.
These factors are important to the individual and can
act as personal indicators that personal, social, and cli-
nical recovery have been achieved [31–33]. Further, a
detailed account of the components included in success-
ful interventions could be useful for tailoring a practical
therapeutic toolkit for people with common mental dis-
order with psychotic experiences. However, the contri-
bution of specific components to the effectiveness of
psychological interventions is under-studied. A compre-
hensive review of the literature is required.
Methods
Aim
The aim of this systematic review is to provide an evidence
synthesis of the effectiveness and cost-effectiveness of all
psychological interventions to reduce psychotic experiences
and the associated distress through meta-analysis, sup-
ported by narrative synthesis where appropriate. To this
end, the proposed systematic review will answer the follo-
wing questions:
1. Which psychological interventions have been
effective for the treatment of psychotic experiences
and have improved outcomes related to psychotic
symptoms, symptoms of depression and anxiety,
distress, functioning (including social, occupational,
and academic), and quality of life?
2. What are the common components of
psychological interventions for psychotic
experiences that improve outcomes related to
psychotic symptoms, symptoms of depression and
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anxiety, distress, functioning (including social,
occupational, and academic), and quality of life?
3. Which psychological interventions used for the
treatment of psychotic experiences are cost-
effective?
In fulfilling these aims, this review will provide an
overview of psychological interventions for psychotic
experiences and give recommendations for the treatment
of these experiences and their associated distress. Add-
itionally, it will contribute to the development of a
tailored intervention for use within IAPT services as part
of the NIHR Programme Grant for Applied Research
(RP-PG-0616-20003): Tailoring evidence-based psycho-
logical therapY for People with common mental disorder
including Psychotic EXperiences (TYPPEX).
The review will follow the PRISMA guidelines [34], and
this protocol will adhere to the PRISMA-P protocol guid-
ance [35]. The review has been registered in the PROS-
PERO International Prospective Register of Systematic
Reviews (registration number: CRD42016033869; 22 May
2018 version).
Population
Participant characteristics
We will include studies of adolescents and adults aged
16 years and older in order to reflect the ages when most
of these clinical experiences tend to appear and become
more clinically distinctive [36] and to focus on interven-
tions that may be applied in adult mental health settings,
such as IAPT services, with no restrictions on sex, gen-
der, or ethnicity. If studies include participants younger
than 16 and do not separate outcome data by age, we
will only include those studies where the mean age of
the participants is ≥ 16.
Diagnosis
Our condition of interest is psychotic experiences as
measured by a valid and reliable measure (clinician rated
or self-report). As different authors use diverse terms to
describe these experiences, we will also include studies
whose interventions focused on the following diagnoses:
at-risk mental state, attenuated psychosis, psychosis-like
experiences, unusual experiences, sub-threshold psych-
osis, prodromal psychosis, schizotypal disorders, psych-
otic depression, and psychotic anxiety. We will further
include interventions for people at ultra-high risk (UHR)
and clinical high risk (CHR) for psychosis. We will not
include studies focused on populations with diagnoses of
psychosis, first episode psychosis (FEP), schizophrenia,
or bipolar disorder.
We will further include studies where patients have
depression, anxiety, and/or substance use in addition to
their psychotic experiences, due to their high prevalence
in this population. We will exclude studies focused on
participants with psychotic experiences and any of the
following: intellectual disability, epilepsy, dementia,
Alzheimer’s disease, Parkinson’s disease, and Hunting-
ton’s disease. The purpose of this exclusion criterion is
to control for confounding in the assessment of inter-
vention effect.
Intervention
We will include studies that focus on psychological and
psychosocial therapies or interventions. Using Cox and col-
leagues’ 2014 review as guidance [37], we have included all
psychological interventions as divided into cognitive behav-
ioural therapy, integrative therapy, humanistic therapy, and
psychodynamic therapy. Common examples of psycho-
logical therapies are presented below, with their main ele-
ments listed after:
 Cognitive behavioural therapy (CBT)—cognitive
restructuring and behavioural change
 Behavioural therapy (BT)—focuses on learned
behaviours and how the context or environment
influences those behaviours
 Cognitive therapy (CT)—cognitive restructuring
 Mindfulness therapy—focusing on and attending to
present experiences
 Interpersonal therapy (IPT)—improving social
relationships and social skills
 Problem-solving therapy (PST)—identifying and
creating solutions to current problems
 Play therapy (PT)—increasing participation in
activities
 Humanistic therapy (HT)—supportive, empathetic
therapy without judgement or advice
 Psychodynamic therapy (PDT)—interpretation and
transference to resolve unconscious conflict
We will include studies whose interventions provide
other relevant psychological interventions not listed
above (please see search strategy item S4 for more detail
on psychological interventions included in the search.)
We will exclude studies in which psychiatric medica-
tion was provided as part of the intervention protocol.
We have not placed a restriction on the proportion of
participants taking medication for depressive or anxiety
disorders, but will exclude studies in which greater than
25% of participants received antipsychotics due to clin-
ical need. This exclusion criterion aims to limit con-
founding due to the use of antipsychotic medication.
We have placed no restriction on intervention pro-
viders (e.g. clinical psychologist vs. psychiatrists), dur-
ation of intervention, or mode of delivery (e.g. online vs.
face-to-face).
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Comparators
For inclusion in the meta-analysis, we will require stu-
dies to have a comparator, which may be another type of
psychological intervention or treatment as usual, but
which must not be psychopharmacological/dietary in
nature. We will also include studies without a compara-
tor (e.g. pre-post studies, cohort studies) within our
narrative synthesis. The field of psychological therapy
for psychotic experiences is still relatively new, and
although some therapy frameworks may currently be at
preliminary stages of investigation (i.e. not ready for
evaluation in controlled trials), they are still of interest
to our review. We have not placed any restrictions on
comparators in relation to cost-effectiveness.
Outcomes
Our primary outcome of interest is the proportion of
participants achieving symptomatic recovery or remission
of psychotic experiences, as determined by validated
clinician-rated or self-report measures (e.g. the Compre-
hensive Assessment of At-Risk Mental States (CAARMS)
[38]). Secondary outcomes of interest include changes in
psychotic symptoms, distress, anxiety and depressive
symptoms, functioning (including social, occupational,
and academic functioning), and quality of life. These out-
come measures were chosen because of their potential to
inform psychological interventions to improve health out-
comes for people with psychotic experiences. We will
further include studies that report economic outcomes
(broadly defined), including costs, resource use, employ-
ment impacts, lost productivity, quality-adjusted life years
(QALYs), or disability-adjusted life years (DALYs). Eco-
nomic data will be included to determine whether these
interventions are economically viable options for imple-
mentation in current services.
We will exclude studies that solely report on the binary
outcome of conversion or non-conversion to psychotic
disorders. As stated above, the rationale behind this exclu-
sion lies in the low rates of transition from having psych-
otic experiences to frank psychotic disorder (estimated at
approximately 30% over a 2-year follow-up period) [39].
Furthermore, the therapy that will be designed for the
TYPPEX programme does not seek to prevent transition,
but rather to provide symptomatic recovery, and measures
of transition do not explicitly report on symptomatic
recovery or improvement.
Setting
We have not placed any restriction on setting.
Study design
We will include all experimental study designs that pro-
vide data on our primary and/or secondary outcomes, as
measured by a validated and reliable tool, including but
not limited to randomised controlled trials (RCTs), con-
trolled clinical trials (CCTs), and pre-post designs.
We will not include qualitative studies because they can-
not adequately address our aims. We will further exclude
the following publication types: books, letters, trade articles,
magazines, opinions/editorials, replies/commentaries, pos-
ters, conference abstracts (in absence of full texts), reviews,
protocols, guidelines, service evaluations, and case studies.
Miscellaneous exclusion criteria
We will exclude papers from before the year 2000, which
was when the at-risk mental state [38] became widely
adopted. We have no exclusion criteria for publication
language, as long as an English abstract is provided.
Information sources
We will search the following online databases, with an
end date of 15 December 2018: MEDLINE, Excerpta
Medica DataBase (Embase), PsycINFO, all Cochrane
databases, British Nursing Index (BNI), Cumulative
Index to Nursing and Allied Health Literature
(CINAHL), Health Management Information Consor-
tium (HMIC), Education Resources Information Center
(ERIC), and EconLit. We will further hand search refer-
ence lists of relevant reviews and journals for additional
citations. We will also search the World Health
Organization International Clinical Trials Registry Plat-
form (WHO ICTRP) for relevant trials. For trials that
have not published results 30 months after their antici-
pated completion date, we will contact authors to pro-
vide data. We will further search the following grey
literature databases for dissertations and conference pa-
pers: PsycINFO, CINAHL, Google Scholar, EThOS, and
Open Grey.
Search strategy
The search strategies for each of the databases were
developed in partnership with experts at the University
of Cambridge Medical Library. Please see the Appendix
for the search strategy that will be entered in PsycINFO,
CINAHL, and ERIC (all accessed via EBSCO). We did
not use any peer review service for our search strategy
(e.g. Peer Review of Electronic Search Strategies,
PRESS).
Study records
Data management
EndNote X8 will be used to manage records throughout
the review process to identify and remove duplicates, ob-
tain full texts, and categorise papers according to inclu-
sion or exclusion.
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Study selection
After removal of duplicate citations, studies will be
screened in two stages: title/abstract and full text. DR
and ES will complete title and abstract screening and full
text screening independently using the inclusion and ex-
clusion criteria described above. DR and ES will discuss
all disputed papers, and a senior team member (JP) will
resolve any discrepancy. Where there is not sufficient
data to determine inclusion or exclusion, protocols for
that study will be consulted if available, and study
authors will be contacted to request any data missing
from methods or results. For each stage of screening, we
will calculate Cohen’s kappa to measure inter-rater
agreement. We have defined kappa quality as follows:
values ≤ 0 as no agreement, 0.01–0.20 as no to slight
agreement, 0.21–0.40 as fair agreement, 0.41–0.60 as
moderate agreement, 0.61–0.80 as substantial agree-
ment, and 0.81–1.00 as nearly perfect agreement [40]. In
the event of a poor Cohen’s kappa, we will have a third
reviewer review all papers selected for full-text review
and will triangulate using this third opinion.
Data extraction
Two trained research assistants (DR and ES) will extract
data from the included studies. All extraction and com-
ponents tables will be piloted with a small sample of pa-
pers (N = 5) before they are used for the review and will
be amended as necessary after piloting. The reviewers
will independently extract study characteristics, outcome
data, and intervention components, and JP will resolve
any discrepancies not solved through discussion between
DR and ES. Again, where variables of interest are not
clearly presented in the studies, intervention protocols
will be referenced and/or study authors contacted.
Study and sample characteristics
In terms of general study characteristics, we will extract
the following information:
 Author
 Location
 Study design
 Sample size
 Sample characteristics (age, sex, ethnicity, etc.)
 Participation and attrition rates
Outcome data
To measure the effectiveness of the intervention in
terms of our primary and secondary outcomes, we will
extract the following:
 Which outcomes were used (primary and
secondary)
 Primary criterion used to determine at-risk mental
state
 Tools used to measure outcomes
 Terminology used to represent psychotic
experiences (i.e. diagnosis)
 Duration of follow-up measurement
 Baseline symptom severity for all outcomes
 Findings/outcomes (only those of interest in our
systematic review will be extracted) as measured
by authors
Intervention components
We will also extract all available intervention compo-
nents from each of the studies, regardless of intervention
outcome. We will extract information both inherent to
the intervention (e.g. characteristics of the intervention
or therapy itself ) as well as information about its imple-
mentation (e.g. characteristics relating to structure of
training/supervision, delivery). If this information is not
explicit in included studies, we will consult protocol/
intervention design papers.
We will extract the following components into a se-
parate ‘intervention components’ table:
 Theoretical framework of the intervention (i.e. type
of therapy, as categorised above)
 Description of the intervention (including four a
priori components of interest: assessment of
problems and goals, formulation, homework, and
active change strategies [41])
 Intervention setting
 Number of centres providing intervention
 Individual who delivered treatment (e.g. clinician,
counsellor)
 Mode of delivery (e.g. telephone, face to face)
 Intervention intensity (duration of treatment,
maximum/minimum/median number of sessions,
and length/frequency of sessions)
 Group size (if group-based intervention)
 Whether there was signposting to other services
 Manualisation of intervention (yes/no)
 Fidelity to treatment protocol (measured/not
measured)
Critical appraisal of included studies
Risk of bias and study quality will be assessed at study
level using two quality appraisal tools. Two reviewers
(DR and ES) will independently rate each study in terms
of quality and risk of bias. Discrepancies will be dis-
cussed, and if not resolved between the two reviewers,
JP will help to make a final decision. Two different tools
will be used to evaluate quantitative studies and eco-
nomic evaluation studies.
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To assess the risk of bias and study quality in quantita-
tive studies, we will use the Effective Public Health Prac-
tice Project’s Quality Assessment Tool for Quantitative
Studies [42]. This tool was designed to appraise a number
of different study types, including randomised controlled
trials (RCTs), controlled clinical trials (CCTs), cohort ana-
lytic studies, case-control studies, cohort studies, and
interrupted time series studies. It is an accepted tool for
the use of systematic reviews of intervention effectiveness
[43]. The tool contains eight different sections, each with
multiple questions: selection bias, study design, con-
founders, blinding, data collection methods, withdrawals
and drop-outs, intervention integrity, and analyses. Each
section receives a score of 1 (strong), 2 (moderate), or 3
(weak), and a final score is determined by the number of
'weak' ratings.
Economic studies will be assessed using the Drum-
mond checklist [44], as recommended by the Cochrane
Handbook for Systematic Reviews of Interventions [45].
The Drummond checklist contains 35 questions with
four answers each (‘yes,’ ‘no,’ ‘not clear,’ and ‘not appro-
priate), divided into three categories: study design, data
collection, and analysis and interpretation of results.
There is no final score assigned to papers, so quality will
be reported in narrative style.
Data synthesis and analysis
Narrative synthesis
When presenting results from uncontrolled studies (e.g.
pre-post designs, cohort studies), we will use Popay and
colleagues’ guidance for narrative synthesis [46]. We will
further use this guidance to report the common compo-
nents of effective interventions. The process may involve
the following elements, where feasible and appropriate:
 Develop a synthesis of included studies’
findings (i.e. describe patterns across
studies)
 Explore relationships between the
findings (i.e. examine factors related to
intervention effects)
 Assess the overall robustness of
the evidence as a whole
(i.e. comment on the generalisability
of findings) [46]
Our narrative synthesis will inform Research Question
1 by:
 Synthesising comparative findings from controlled
studies not included in meta-analyses (e.g. where
there are not enough studies to conduct meta-
analysis)
 Examining changes from baseline to follow-up mea-
surements in any of our outcomes of interest for all
studies
The synthesis will also address Research Question 2
by:
 Providing a qualitative account of our four a priori
components of interest—assessment of problems
and goals, formulation, homework, and active
change strategies [41]—in relation to intervention
effect for studies not included in our meta-analyses
 Providing a qualitative account of any other
variables from our components table in relation to
the intervention effect for all studies
Economic analysis
Economic studies will be presented in tables describ-
ing the study characteristics and study results. These
will be described in a narrative approach and will in-
clude discussion of study quality as well as discussion
of study homogeneity. Because cost-effectiveness of
one intervention compared with another is heavily
dependent on the methods of economic evaluation
used in identified studies, decision rules [47] will vary
dependent on the
 Method of economic evaluation selected (e.g. cost-
effectiveness analysis, cost-utility analysis, cost-
benefit analysis, etc.),
 Outcome measure selected (e.g. QALYs, DALYs,
clinical measures, etc.), and
 Study setting (different countries have different
thresholds an intervention must achieve to be
considered cost-effective, so whilst in England, the
threshold is £20,000–£30,000 per QALY, the thresh-
old will be different in different countries and for
different currencies).
Meta-analysis
If two or more RCT/CCT studies report on a given out-
come of interest, we will address Research Question 1 by
quantitatively synthesising the results via random-effects
meta-analysis (we assume a priori that there will be het-
erogeneity between the included studies; random-effects
estimates of effect size are therefore more conservative).
Separate meta-analyses will be conducted per outcome.
We will compare studies on the basis of the framework
of psychological intervention and will group controls
into the following categories: psychological therapies/in-
terventions and treatment as usual (we will not include
pharmacological or dietary interventions, as these would
not align with our aims or inclusion/exclusion criteria).
If possible, we will perform subgroup analyses by clinical
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versus non-clinical study populations, as they may
feature differing thresholds in terms of inclusion.
To answer Research Question 2, we will further per-
form subgroup analyses by our four a priori components
of interest, given that there are at least two studies in
each comparison group (i.e. two studies with the compo-
nent, and two studies without the component).
Our outcomes will be assessed as follows:
 Our primary outcome, i.e. the proportion of
participants achieving remission/recovery from
psychotic experiences, will be analysed through
calculation of an odds ratio (OR) with a 95%
confidence interval (CI).
 Our secondary outcomes, i.e. changes in positive/
negative psychotic symptoms, distress, functioning,
depression, anxiety, and quality of life, will be
analysed using standardised mean differences (with
95% CIs).
Where available, we will use intention-to-treat data
in our analysis. We will not use meta-analysis to
examine outcome data from uncontrolled studies or
economic data.
Assessment of heterogeneity
We will consider clinical heterogeneity [45] (e.g. diver-
sity of intervention frameworks) before conducting our
meta-analysis, to help ensure this method is appropriate
for our data. If meta-analysis is appropriate, we will
quantitatively assess heterogeneity using a chi-squared
test, Q statistic, and I2 statistic. We will use the approxi-
mate guidelines suggested by Higgins and colleagues
[48], which state that I2 values of 0%, 25%, 50%, and 75%
represent no, low, moderate, and high heterogeneity,
respectively.
Sensitivity analysis
We will perform sensitivity analyses within the meta-
analysed studies to explore the effect of studies with a
high risk of bias (e.g. studies that do not use intention-
to-treat reporting, studies with high attrition, and studies
with missing data). We will do this by removing those
studies that received a ‘high’ risk of bias rating in any of
the bias sections of the Effective Public Health Practice
Project Quality Assessment Tool from the meta-analysis
and re-computing a pooled estimate of intervention
effect. We will further conduct an analysis to assess the
impact of removing CCTs on the pooled effect estimate,
i.e. using only RCTs to estimate therapeutic effects.
Assessment of meta-biases
We will assess bias (e.g. publication bias, language
bias, citation bias) through an examination of funnel
plot symmetry (if ten or more studies are included in
the meta-analysis) and Egger’s test of the intercept
[49]. Where study protocols are available, we will exa-
mine outcomes reporting bias by comparing outcomes
listed in the protocol with those presented in the
published report. If appropriate, sensitivity analyses
may also be conducted to determine the impact of
outcomes reporting bias on meta-analytic results.
Confidence in cumulative evidence
In order to assess the confidence in the cumulative
evidence, we will use the GRADE approach, developed by
the Grading of Recommendations Assessment, Develop-
ment and Evaluation working group [50]. The GRADE as-
sessment method covers the following domains: study
design, study quality, consistency, and directness [50]. As
recommended by the GRADE Working Group, we will
begin by ranking according to study design (randomised
trials are rated ‘high,’ observational studies ‘low’). We will
then downgrade for study quality limitations (measured
by our quality rating tools), inconsistency (measured by
unexplained inconsistency in results), uncertainty about
directness, imprecise or sparse data, or likelihood of
reporting bias (if possible to measure). We will upgrade
for strong evidence of association or indication of
dose-response effects. We will also upgrade if adjustment
for all plausible residual confounders would likely have re-
duced the magnitude of observed intervention effect [50].
In making final assessments, we will use the GRADE
working group’s recommendations of four levels of evi-
dence quality: high, moderate, low, and very low [51].
Discussion
Available evidence suggests that psychotic experiences
are often present in individuals with common mental
disorders such as anxiety and depression, and that rather
than solely indicating an imminent transition to a psych-
otic disorder, they are frequently indicators of severity of
common mental distress. Many of these individuals seek
help in general care settings, such as IAPT services
within primary care, where psychotic experiences are
neither measured nor treated. This review will provide
an evidence synthesis of the effectiveness and cost-ef-
fectiveness of any psychological interventions used for
the treatment of psychotic experiences. The identifica-
tion of specific components associated with intervention
effectiveness will augment existing evidence that can
inform the development of a new, tailored intervention to
improve outcomes related to psychotic symptoms, anxiety
and depression, distress, functioning (including social, oc-
cupational, and academic), and quality of life. To the au-
thors’ knowledge, this is the first systematic review that
explicitly and exclusively intends to inform the
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development of therapeutic interventions to ameliorate
psychotic experiences and their associated distress.
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Appendix
Table 1 Search strategy for PsycINFO
S1 sub-clinical or non-psychotic or ((“high risk*” or “clinical risk*” or “at risk”) N5 psychosis) or (prodrom*) or “at risk mental state” or subthreshold or
“pre-psychotic” or “psychotic-like”
S2 psychotic or vision* or voice* or hallucinat* or “see* thing*” or paranoi* or psychosis or delusion* or psychopatholog* or percept* or suspicious*
or “anomalous experiences” or “unusual experiences” or “atypical experiences” or “abnormal experiences” or “dissociation”
S3 “psychological treatment*” or cbt or “cognitive behav* therap*” or “psychological intervention*” or “cognitive therap*” or emdr or “eye
movement desensiti?ation reprocessing” or emdt or “eye movement desensiti?ation therapy” or therap* or psychosocial or psychoeducation* or
“family-focused” or “meta-cognitive therapy” or “meta-cognitive treatment” or “trans-diagnostic treatment” or “trans-diagnostic therapy”
S4 ((DE “Cognitive Therapy”) OR (DE “Cognitive Behavior Therapy” OR DE “Acceptance and Commitment Therapy”)) OR (DE “Psychotherapy” OR DE
“Adlerian Psychotherapy” OR DE “Adolescent Psychotherapy” OR DE “Affirmative Therapy” OR DE “Analytical Psychotherapy” OR DE “Autogenic
Training” OR DE “Behavior Therapy” OR DE “Brief Psychotherapy” OR DE “Brief Relational Therapy” OR DE “Child Psychotherapy” OR DE “Client
Centered Therapy” OR DE “Cognitive Behavior Therapy” OR DE “Conversion Therapy” OR DE “Eclectic Psychotherapy” OR DE “Emotion Focused
Therapy” OR DE “Existential Therapy” OR DE “Experiential Psychotherapy” OR DE “Expressive Psychotherapy” OR DE “Eye Movement
Desensitization Therapy” OR DE “Feminist Therapy” OR DE “Geriatric Psychotherapy” OR DE “Gestalt Therapy” OR DE “Group Psychotherapy” OR
DE “Guided Imagery” OR DE “Humanistic Psychotherapy” OR DE “Hypnotherapy” OR DE “Individual Psychotherapy” OR DE “Insight Therapy” OR
DE “Integrative Psychotherapy” OR DE “Interpersonal Psychotherapy” OR DE “Logotherapy” OR DE “Narrative Therapy” OR DE “Network Therapy”
OR DE “Persuasion Therapy” OR DE “Primal Therapy” OR DE “Psychoanalysis” OR DE “Psychodrama” OR DE “Psychodynamic Psychotherapy” OR
DE “Psychotherapeutic Counseling” OR DE “Rational Emotive Behavior Therapy” OR DE “Reality Therapy” OR DE “Relationship Therapy” OR DE
“Solution Focused Therapy” OR DE “Supportive Psychotherapy” OR DE “Transactional Analysis”)
S5 S3 OR S4
S6 (((DE “Hallucinations” OR DE “Auditory Hallucinations” OR DE “Drug Induced Hallucinations” OR DE “Hypnagogic Hallucinations” OR DE “Visual
Hallucinations”) OR (DE “Auditory Hallucinations”)) OR (DE “Paranoia” OR DE “Paranoia (Psychosis)” OR DE “Folie A Deux”)) OR (DE “Psychosis” OR
DE “Acute Psychosis” OR DE “Affective Psychosis” OR DE “Alcoholic Psychosis” OR DE “Capgras Syndrome” OR DE “Childhood Psychosis” OR DE
“Chronic Psychosis” OR DE “Experimental Psychosis” OR DE “Hallucinosis” OR DE “Paranoia (Psychosis)” OR DE “Postpartum Psychosis” OR DE
“Reactive Psychosis” OR DE “Schizophrenia” OR DE “Senile Psychosis” OR DE “Toxic Psychoses”)
S7 S2 OR S6
S8 (DE “Prodrome”) OR (DE “At Risk Populations”)
S9 S1 OR S8
S10 S5 AND S7 AND S9
Filters: 2000–2018
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